

Trust Headquarters  
 Russell's Hall Hospital  
 Dudley  
 West Midlands  
 DY1 2HQ

**Ref:** FOI-012026-0002185

**Date:** 27<sup>th</sup> February 2026

**Address / Email:**

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000, please see response below.

Q1. How many patients has your Trust treated in the past 12 months (January - December 2025) for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Trust do you refer patients needing treatment to? – **66**

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated by the Trust in the past 6 months on the following treatments:

• BR (bendamustine + rituximab)	<b>0</b>
• Brukinsa (zanubrutinib)	<b>12</b>
• Calquence (acalabrutinib)	<b>34</b>
• Calquence (acalabrutinib) + Gazyva (obinutuzumab)	<b>0</b>
• Calquence (acalabrutinib) + Venclyxto (venetoclax)	<b>0</b>
• Calquence (acalabrutinib) + Venclyxto (venetoclax) + Gazyva (obinutuzumab)	<b>0</b>
• FCR (fludarabine + cyclophosphamide + rituximab)	<b>0</b>
• Fludarabine Monotherapy	<b>0</b>
• Gazyva (obinutuzumab) + chlorambucil	<b>0</b>
• Imbruvica (ibrutinib)	<b>6</b>
• Venclyxto (venetoclax)	<b>10</b>
• Venclyxto (venetoclax) + Gazyva (obinutuzumab)	<b>1</b>
• Venclyxto (venetoclax) + rituximab	<b>3</b>
• Zydelig (idelalisib) + rituximab	<b>0</b>
• Imbruvica (Ibrutinib) +Venclyxto (venetoclax)	<b>0</b>
• Any other systemic anti-cancer therapy	<b>6</b>

Q3. How many Chronic Lymphocytic Leukaemia (CLL) patients have received treatment for relapsed/refractory CLL in the past 6 months with the following:

- Brukinsa (zanubrutinib)
- Calquence (acalabrutinib)
- Imbruvica (ibrutinib)
- Venclyxto (venetoclax)
- Zydelig (idelalisib) + rituximab
- Any other systemic anti-cancer therapy

**The Trust does not hold this information in a reportable format.**

***When information is not in a reportable format***

***The ICO guidance clearly states “FOIA only applies to information that a public authority already holds in recorded form at the time of a request. If you don’t hold a particular piece of information that someone has asked for, you don’t have to create it”.***

Q4. If your Trust does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If yes, please can you provide details of the ongoing trials.

**FLAIR Trial – 2 patients**  
**STATIC Trial – 4 patients**

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell’s Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team**  
**The Dudley Group NHS Foundation Trust**